BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7797405)

  • 1. Effect of L-propionyl carnitine on in-vitro membrane alteration of sickle-cell anaemia erythrocytes.
    Ronca F; Palmieri L; Malengo S; Bertelli A
    Int J Tissue React; 1994; 16(4):187-94. PubMed ID: 7797405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-propionyl carnitine protects erythrocytes and low density lipoproteins against peroxidation.
    Bertelli A; Conte A; Ronca G
    Drugs Exp Clin Res; 1994; 20(5):191-7. PubMed ID: 7875055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of L-propionyl carnitine on some properties of erythrocytes and leukocytes of alcohol abusers.
    Conte A; Bianchi I; Guazzelli M; Taponeco G; Bertelli A; Ronca G
    Int J Tissue React; 1995; 17(1):21-31. PubMed ID: 7499061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of propionyl carnitine against peroxidative damage to arterial endothelium membranes.
    Bertelli A; Conte A; Ronca G; Segnini D; Yu G
    Int J Tissue React; 1991; 13(1):41-3. PubMed ID: 1889962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of beta-thalassaemic erythrocytes from oxidative stress by propionyl carnitine.
    Palmieri L; Ronca F; Malengo S; Bertelli A
    Int J Tissue React; 1994; 16(3):121-9. PubMed ID: 7852033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of isolated perfused working rat heart from oxidative stress by exogenous L-propionyl carnitine.
    Ronca G; Ronca F; Yu G; Zucchi R; Bertelli A
    Drugs Exp Clin Res; 1992; 18(11-12):475-80. PubMed ID: 1308473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
    Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C
    Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A; De Martini D; Flore R; Gaetani E; Gasbarrini A; Gerardino L; Pola R; Santoliquido A; Serricchio M; Tondi P; Nolfe G
    Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats.
    Gómez-Amores L; Mate A; Revilla E; Santa-María C; Vázquez CM
    Life Sci; 2006 Mar; 78(17):1945-52. PubMed ID: 16263137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine-induced lipid peroxidation and propionyl carnitine protective effect.
    Longoni B; Giovannini L; Migliori M; Bertelli AA; Bertelli A
    Int J Tissue React; 1999; 21(1):7-11. PubMed ID: 10463135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-propionyl carnitine reduces toxicity correlated to cyclosporine-induced intracellular ATP concentrations.
    Giovannini L; Migliori M; De Pietro S; Taccola D; Panichi V; Bertelli AA; Bertelli A
    Drugs Exp Clin Res; 1999; 25(4):173-7. PubMed ID: 10442274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormality of erythrocyte membrane n-3 long chain polyunsaturated fatty acids in sickle cell haemoglobin C (HbSC) disease is not as remarkable as in sickle cell anaemia (HbSS).
    Ren H; Ghebremeskel K; Okpala I; Ugochukwu CC; Crawford M; Ibegbulam O
    Prostaglandins Leukot Essent Fatty Acids; 2006 Jan; 74(1):1-6. PubMed ID: 16314081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased susceptibility of erythrocyte membrane lipids to peroxidation in sickle cell disease.
    Essien EU
    Cent Afr J Med; 1994 Aug; 40(8):217-20. PubMed ID: 7813000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickling and Vinblastine.
    Ricci G; Zavagli G
    Biomed Pharmacother; 1983; 37(2):85-7. PubMed ID: 6616035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of light irreversibly sickled cells during deoxygenation-oxygenation cycles.
    Horiuchi K; Asakura T
    J Lab Clin Med; 1987 Nov; 110(5):653-60. PubMed ID: 3668362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of irreversibly sickled cells in reducing the osmotic fragility of red cells in sickle cell anemia.
    Figueiredo MS; Zago MA
    Acta Physiol Pharmacol Latinoam; 1985; 35(1):49-56. PubMed ID: 2932889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glyceraldehyde on the structural and functional properties of sickle erythrocytes.
    Nigen AM; Manning JM
    J Clin Invest; 1978 Jan; 61(1):11-9. PubMed ID: 618907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The irreversibly sickled cell.
    Smith CM; Krivit W; White JG
    Am J Pediatr Hematol Oncol; 1982; 4(3):307-15. PubMed ID: 7149169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products.
    Bueno R; Alvarez de Sotomayor M; Perez-Guerrero C; Gomez-Amores L; Vazquez CM; Herrera MD
    Life Sci; 2005 Sep; 77(17):2082-97. PubMed ID: 15958269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheological activity of propionyl L-carnitine.
    Pola P; Flore R; Tondi P; Nolfe G
    Drugs Exp Clin Res; 1991; 17(3):191-6. PubMed ID: 1914846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.